全球胃輕癱市場：各地區與國家分析與預測（2025-2035）

Gastroparesis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035

出版日期: 2025年06月30日 | 出版商:

BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄圖表

胃輕癱市場的主要成長要素之一是第1型和第2型糖尿病盛行率的上升。糖尿病是糖尿病性胃輕癱的主要原因之一，這種疾病是由於高血糖損害控制胃部肌肉的迷走神經而發生的。這種神經損傷會導致排放延遲，這是胃輕癱的典型症狀。隨著糖尿病患者人數的增加，尤其是在開發中國家，糖尿病性胃輕癱的發生率也在上升，這推動了對該疾病治療和管理的需求。

此外，血糖控制不佳的糖尿病患者數量不斷增加，需要創新的解決方案來解決胃輕癱的併發症，如噁心、嘔吐、早飽、血糖值難以預測等。患者數量的不斷成長，以及胃電刺激設備和胃腸動力預防等先進診斷和治療方法的發展，正在推動市場成長。

儘管胃輕癱市場正在成長，但仍存在一些挑戰阻礙其發展。其中最主要的挑戰之一是缺乏早期診斷或漏診。胃輕癱常與其他消化系統疾病（例如大腸激躁症(IBS) 和胃食道逆流症 (GERD)）重疊，且症狀特異性，導致誤診和延遲診斷。

診斷本身很複雜，需要進行胃排空排放顯像、呼吸檢測和上消化道內視鏡等專門檢查，而並非所有醫療機構都提供這些檢查。由於缺乏標準化的檢查，且先進診斷設備的使用受限，診斷常常被延誤，直至病情發展到嚴重階段，從而導致治療困難。

此外，治療方案有限。目前使用的胃腸促動力藥物和胃電刺激設備並非對所有患者都有效，副作用也可能限制其使用。我們有必要發展針對潛在病因的治療方法，尤其是針對糖尿病性胃輕癱等潛在疾病。

此外，長期管理、專門治療和反覆就診相關的高昂醫療費用給患者和醫療保健系統帶來了沉重的負擔，阻礙了患者獲得治療的機會和接受治療，特別是在資源有限的地區，並且儘管對更有效的治療方法有需求，但仍阻礙了市場成長。

本報告調查了全球胃輕癱市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局以及主要企業的概況。

Gastroparesis is a gastrointestinal disorder characterized by delayed gastric emptying, where the stomach takes too long to empty its contents, despite the absence of any physical obstruction in the stomach or intestines. This condition is typically caused by nerve damage, particularly to the vagus nerve, which plays a critical role in controlling the stomach and intestinal muscles. When the vagus nerve is damaged, it disrupts the normal motility (movement) of the stomach, resulting in difficulty effectively emptying the stomach. Symptoms of gastroparesis include nausea, vomiting (especially after meals), bloating, early satiety, abdominal pain, loss of appetite, weight loss, heartburn, and unpredictable blood sugar levels, particularly in diabetic patients.

Common causes of the condition include diabetes, where elevated blood sugar levels damage the vagus nerve, idiopathic gastroparesis (where the cause remains unknown), and post-surgical gastroparesis following stomach or esophageal surgery. Neurological conditions like Parkinson's disease and multiple sclerosis can also lead to gastroparesis, as well as the use of certain medications such as opioids. Diagnosis typically involves gastric emptying scintigraphy, breath tests, and imaging techniques like upper endoscopy or ultrasound to rule out other potential conditions.

Treatment for gastroparesis aims to alleviate symptoms and improve gastric motility, and may include dietary modifications, medications like prokinetic agents (e.g., metoclopramide), antiemetics to control nausea, gastric electrical stimulation (GES) devices, or surgical interventions like pyloroplasty in severe cases. While gastroparesis can significantly impact a person's quality of life, proper management strategies enable most patients to control symptoms and improve their ability to eat and absorb nutrients.

One of the key drivers of the Gastroparesis market is the increasing prevalence of diabetes, particularly type 1 and type 2 diabetes. Diabetes is one of the primary causes of diabetic gastroparesis, a condition that occurs when high blood sugar levels damage the vagus nerve, which controls the muscles of the stomach. This nerve damage leads to delayed gastric emptying, a hallmark symptom of gastroparesis. As the global rates of diabetes continue to rise, particularly in developing countries, the incidence of diabetic gastroparesis increases, thereby driving the demand for effective treatments and therapies to manage the condition.

Additionally, the growing number of individuals with poorly controlled diabetes has increased the need for innovative solutions to manage the complications associated with gastroparesis, such as nausea, vomiting, early satiety, and unpredictable blood sugar levels. This growing patient population, combined with the development of advanced diagnostic tools and therapeutic options like gastric electrical stimulators and prokinetic agents, is fuelling the growth of the gastroparesis market.

Despite the growth of the Gastroparesis market, several challenges continue to hinder its progress. One of the primary challenges is the lack of early diagnosis and underdiagnosis of the condition. Gastroparesis often presents with symptoms that are non-specific and overlap with other gastrointestinal disorders, such as irritable bowel syndrome (IBS), acid reflux, or gastroesophageal reflux disease (GERD). As a result, many patients are misdiagnosed or experience delays in receiving the correct diagnosis.

The diagnostic process itself can be complex and involves specialized tests like gastric emptying scintigraphy, breath tests, and upper endoscopy, which may not always be readily available in all healthcare settings. This lack of standardization in testing and limited access to advanced diagnostics means that gastroparesis is often diagnosed only after significant symptoms develop, complicating treatment.

Additionally, the treatment landscape for gastroparesis remains somewhat limited. While there are treatments available, such as prokinetic agents and gastric electrical stimulators, these options are not always effective for all patients, and side effects can limit their use. The need for more targeted therapies that address the underlying causes of gastroparesis especially in cases like diabetic gastroparesis remains an ongoing challenge in the market.

Furthermore, high healthcare costs associated with long-term management, specialized treatments, and recurrent hospital visits place an additional burden on both healthcare systems and patients, especially in regions with limited resources. These challenges hinder the overall accessibility and adoption of existing treatments, despite the growing demand for more effective solutions.

The global Gastroparesis market is highly competitive, with several leading companies driving innovation and market growth. Companies such as Vanda Pharmaceuticals, Processa Pharmaceuticals, and Neurogastrx are at the forefront, developing novel treatments like VLY-686 (Tradipitant), PC1050, and NGX-4010 that target the underlying causes of gastric motility disorders in gastroparesis.

Other notable players, including CinDome Pharma and Evoke Pharma, are advancing treatment options with therapies like CIN-102 (deudomperidone) and Gimoti (metoclopramide nasal spray), offering more effective and convenient delivery systems for managing nausea and vomiting in gastroparesis patients.

Large pharmaceutical companies such as AbbVie, AstraZeneca, and Boehringer Ingelheim are also contributing to the market by expanding their portfolios with therapies that aim to improve gastric motility and alleviate symptoms associated with gastroparesis. With a focus on innovation, these companies are continuously pushing the boundaries of research and development to provide better treatment options, improve patient quality of life, and capture a larger share of the growing Gastroparesis market.

Market Segmentation:

Segmentation 1: by Region

North America
Europe
Asia-Pacific

The global Gastroparesis market is undergoing significant transformation, fueled by several key factors that are reshaping the landscape of treatment and care. One of the primary drivers is the rising prevalence of diabetes, particularly type 1 and type 2 diabetes, which is one of the leading causes of diabetic gastroparesis. As the incidence of diabetes continues to grow worldwide, so does the demand for more effective and innovative treatments to manage the related complications, including gastroparesis. In parallel, advancements in diagnostic technologies, such as more accurate and accessible gastric emptying scintigraphy and breath tests, are enabling earlier and more accurate diagnoses, allowing for earlier intervention and better patient outcomes.

Furthermore, innovations in treatment options are contributing to market growth, with companies developing new drug formulations, gastric electrical stimulation devices, and biologic therapies designed to address the underlying causes of delayed gastric emptying. These treatments offer patients more targeted and personalized approaches, enhancing their effectiveness and minimizing side effects. As awareness about gastroparesis continues to increase, both among healthcare providers and patients, there is growing recognition of the condition as a treatable and manageable disease, further driving the demand for therapies. The combination of technological advances, increased research and development, and rising healthcare investments is propelling the market forward, positioning it for continued growth and evolution in the coming years.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Gastroparesis Market: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Epidemiology Analysis
1.5 Clinical Trial Analysis
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Gastroparesis Market (Region), ($Billion), 2023-2035

2.1 North America
- 2.1.1 Key Findings
- 2.1.2 Market Dynamics
- 2.1.3 Market Sizing and Forecast
  - 2.1.3.1 North America Gastroparesis Market, by Country
    - 2.1.3.1.1 U.S.
2.2 Europe
- 2.2.1 Key Findings
- 2.2.2 Market Dynamics
- 2.2.3 Market Sizing and Forecast
  - 2.2.3.1 Europe Gastroparesis Market, by Country
    - 2.2.3.1.1 Germany
    - 2.2.3.1.2 U.K.
    - 2.2.3.1.3 France
    - 2.2.3.1.4 Italy
2.3 Asia Pacific
- 2.3.1 Key Findings
- 2.3.2 Market Dynamics
- 2.3.3 Market Sizing and Forecast
  - 2.3.3.1 Asia Pacific Gastroparesis Market, by Country
    - 2.3.3.1.1 China
    - 2.3.3.1.2 Japan

3. Global Gastroparesis Market: Competitive Landscape and Company Profiles

3.1 Key Strategies and Development
- 3.1.1 Mergers and Acquisitions
- 3.1.2 Synergistic Activities
- 3.1.3 Business Expansions and Funding
- 3.1.4 Product Launches and Approvals
- 3.1.5 Other Activities
3.2 Company Profiles
- 3.2.1 Vanda Pharmaceuticals
  - 3.2.1.1 Overview
  - 3.2.1.2 Top Products / Product Portfolio
  - 3.2.1.3 Top Competitors
  - 3.2.1.4 Target Customers/End-Users
  - 3.2.1.5 Key Personnel
  - 3.2.1.6 Analyst View
- 3.2.2 Processa Pharmaceuticals
  - 3.2.2.1 Overview
  - 3.2.2.2 Top Products / Product Portfolio
  - 3.2.2.3 Top Competitors
  - 3.2.2.4 Target Customers/End-Users
  - 3.2.2.5 Key Personnel
  - 3.2.2.6 Analyst View
- 3.2.3 Neurogastrx
  - 3.2.3.1 Overview
  - 3.2.3.2 Top Products / Product Portfolio
  - 3.2.3.3 Top Competitors
  - 3.2.3.4 Target Customers/End-Users
  - 3.2.3.5 Key Personnel
  - 3.2.3.6 Analyst View
- 3.2.4 CinDome Pharma
  - 3.2.4.1 Overview
  - 3.2.4.2 Top Products / Product Portfolio
  - 3.2.4.3 Top Competitors
  - 3.2.4.4 Target Customers/End-Users
  - 3.2.4.5 Key Personnel
  - 3.2.4.6 Analyst View
- 3.2.5 Evoke Pharma
  - 3.2.5.1 Overview
  - 3.2.5.2 Top Products / Product Portfolio
  - 3.2.5.3 Top Competitors
  - 3.2.5.4 Target Customers/End-Users
  - 3.2.5.5 Key Personnel
  - 3.2.5.6 Analyst View
- 3.2.6 AbbVie Inc.
  - 3.2.6.1 Overview
  - 3.2.6.2 Top Products / Product Portfolio
  - 3.2.6.3 Top Competitors
  - 3.2.6.4 Target Customers/End-Users
  - 3.2.6.5 Key Personnel
  - 3.2.6.6 Analyst View
- 3.2.7 AstraZeneca
  - 3.2.7.1 Overview
  - 3.2.7.2 Top Products / Product Portfolio
  - 3.2.7.3 Top Competitors
  - 3.2.7.4 Target Customers/End-Users
  - 3.2.7.5 Key Personnel
  - 3.2.7.6 Analyst View
- 3.2.8 Boehringer Ingelheim
  - 3.2.8.1 Overview
  - 3.2.8.2 Top Products / Product Portfolio
  - 3.2.8.3 Top Competitors
  - 3.2.8.4 Target Customers/End-Users
  - 3.2.8.5 Key Personnel
  - 3.2.8.6 Analyst View
- 3.2.9 Ironwood Pharmaceuticals
  - 3.2.9.1 Overview
  - 3.2.9.2 Top Products / Product Portfolio
  - 3.2.9.3 Top Competitors
  - 3.2.9.4 Target Customers/End-Users
  - 3.2.9.5 Key Personnel
  - 3.2.9.6 Analyst View